AVENUE THERAPEUTICS INC (ATXI) Stock Fundamental Analysis

NASDAQ:ATXI • US05360L4032

0.42 USD
-0.43 (-50.71%)
At close: Mar 18, 2025
0.3998 USD
-0.02 (-4.81%)
After Hours: 3/18/2025, 8:23:22 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, ATXI scores 2 out of 10 in our fundamental rating. ATXI was compared to 193 industry peers in the Pharmaceuticals industry. While ATXI seems to be doing ok healthwise, there are quite some concerns on its profitability. ATXI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • ATXI had negative earnings in the past year.
  • In the past year ATXI has reported a negative cash flow from operations.
  • ATXI had negative earnings in each of the past 5 years.
  • ATXI had a negative operating cash flow in each of the past 5 years.
ATXI Yearly Net Income VS EBIT VS OCF VS FCFATXI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -360.69%, ATXI is doing worse than 91.84% of the companies in the same industry.
  • ATXI's Return On Equity of -362.76% is on the low side compared to the rest of the industry. ATXI is outperformed by 76.53% of its industry peers.
Industry RankSector Rank
ROA -360.69%
ROE -362.76%
ROIC N/A
ROA(3y)-235.68%
ROA(5y)-231.27%
ROE(3y)-285%
ROE(5y)-290.87%
ROIC(3y)N/A
ROIC(5y)N/A
ATXI Yearly ROA, ROE, ROICATXI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 1K -1K 2K 3K

1.3 Margins

  • ATXI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATXI Yearly Profit, Operating, Gross MarginsATXI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • ATXI has more shares outstanding than it did 1 year ago.
  • ATXI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ATXI Yearly Shares OutstandingATXI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 100K 200K 300K
ATXI Yearly Total Debt VS Total AssetsATXI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

  • ATXI has an Altman-Z score of -35.88. This is a bad value and indicates that ATXI is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -35.88, ATXI is doing worse than 89.80% of the companies in the same industry.
  • ATXI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -35.88
ROIC/WACCN/A
WACCN/A
ATXI Yearly LT Debt VS Equity VS FCFATXI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M -20M

2.3 Liquidity

  • ATXI has a Current Ratio of 2.70. This indicates that ATXI is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of ATXI (2.70) is comparable to the rest of the industry.
  • ATXI has a Quick Ratio of 2.70. This indicates that ATXI is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 2.70, ATXI perfoms like the industry average, outperforming 55.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.7
Quick Ratio 2.7
ATXI Yearly Current Assets VS Current LiabilitesATXI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • ATXI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.44%, which is quite impressive.
EPS 1Y (TTM)83.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-142.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ATXI will show a very strong growth in Earnings Per Share. The EPS will grow by 25.69% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y95.15%
EPS Next 2Y40.88%
EPS Next 3Y25.69%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ATXI Yearly EPS VS EstimatesATXI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2022 2023 2024 2025 2026 -500 -1K -1.5K -2K

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • ATXI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ATXI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATXI Price Earnings VS Forward Price EarningsATXI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATXI Per share dataATXI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

  • ATXI's earnings are expected to grow with 25.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.88%
EPS Next 3Y25.69%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ATXI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

AVENUE THERAPEUTICS INC

NASDAQ:ATXI (3/18/2025, 8:23:22 PM)

After market: 0.3998 -0.02 (-4.81%)

0.42

-0.43 (-50.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-28
Earnings (Next)05-13
Inst Owners10.54%
Inst Owner Change0%
Ins Owners13.22%
Ins Owner Change3.83%
Market Cap802.20K
Revenue(TTM)N/A
Net Income(TTM)-9.47M
Analysts82.86
Price Target8.16 (1842.86%)
Short Float %0%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-300.31%
Min EPS beat(2)-500.37%
Max EPS beat(2)-100.25%
EPS beat(4)1
Avg EPS beat(4)-127.39%
Min EPS beat(4)-500.37%
Max EPS beat(4)158.82%
EPS beat(8)3
Avg EPS beat(8)-138.86%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-33.33%
PT rev (3m)-33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)43%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.31
P/tB 0.31
EV/EBITDA N/A
EPS(TTM)-19.25
EYN/A
EPS(NY)-2
Fwd EYN/A
FCF(TTM)-5.54
FCFYN/A
OCF(TTM)-5.54
OCFYN/A
SpS0
BVpS1.37
TBVpS1.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -360.69%
ROE -362.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-235.68%
ROA(5y)-231.27%
ROE(3y)-285%
ROE(5y)-290.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.7
Quick Ratio 2.7
Altman-Z -35.88
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-142.67%
EPS Next Y95.15%
EPS Next 2Y40.88%
EPS Next 3Y25.69%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-128.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-128.64%
OCF growth 3YN/A
OCF growth 5YN/A

AVENUE THERAPEUTICS INC / ATXI FAQ

What is the ChartMill fundamental rating of AVENUE THERAPEUTICS INC (ATXI) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ATXI.


What is the valuation status for ATXI stock?

ChartMill assigns a valuation rating of 1 / 10 to AVENUE THERAPEUTICS INC (ATXI). This can be considered as Overvalued.


What is the profitability of ATXI stock?

AVENUE THERAPEUTICS INC (ATXI) has a profitability rating of 0 / 10.


How financially healthy is AVENUE THERAPEUTICS INC?

The financial health rating of AVENUE THERAPEUTICS INC (ATXI) is 6 / 10.